The combination therapy of venetoclax and azacitidine (VEN-AZA) has demonstrated substantial benefits for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, particularly for those with specific molecular characteristics, such as NPM1-mutated AML or IDH-mutated AML (1). Here, IDH1 is linked to acute myeloid leukemia.